Ravinath Shetty appointed as Platform COO at Cohance Lifesciences, marking a significant leadership transition in the pharmaceutical operations landscape. Based in Hyderabad, he now leads platform-wide operational strategy, efficiency programs, and cross-functional alignment to support Cohance’s fast-growing CDMO and API capabilities. His appointment reflects the company’s continued focus on strengthening execution excellence as it scales globally.
Before joining Cohance, Ravinath served as President at Apitoria Pharma Private Limited, where he oversaw the organization’s end-to-end operations and strategic initiatives. His leadership helped build operational systems, enhance performance metrics, and strengthen compliance frameworks across manufacturing and quality domains. His tenure positioned Apitoria for sustained growth and operational stability in a dynamic market environment.
Earlier, Ravinath held key senior roles at Aurobindo Pharma, including Associate President, Senior Vice President of Operations, and Vice President. Across nearly five years, he led strategic operations, regulatory compliance, quality systems, risk management, and financial oversight. His experience in driving GMP excellence, Lean Six Sigma initiatives, and plant-level operational control played a critical role in supporting large-scale manufacturing programs.
Ravinath’s foundation was built through impactful leadership stints at Dr. Reddy’s Laboratories, Cipla, Zydus Cadila, Watson Pharmaceuticals, and Lupin. With over three decades of experience across global pharma operations, API manufacturing, regulatory-driven environments, and large-scale site leadership, he brings deep operational expertise to Cohance. His career reflects a consistent trajectory of building resilient, compliant, and future-ready pharmaceutical manufacturing ecosystems.